TCIM
CARM

TIAA CREF Investment Management’s Carisma Therapeutics CARM Stock Holding History

TIAA CREF Investment Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-600
Closed -$34K – 3109
2015
Q2 		$34K Sell
600
-303
-34% -$42.8K ﹤0.01% 3211
2015
Q1 		$161K Hold
903
– – ﹤0.01% 3074
2014
Q4 		$215K Buy
903
+53
+6% +$11.9K ﹤0.01% 3091
2014
Q3 		$189K Buy
850
+29
+4% +$6.89K ﹤0.01% 3090
2014
Q2 		$216K Buy
821
+75
+10% +$18.6K ﹤0.01% 3078
2014
Q1 		$242K Buy
+746
New +$223K ﹤0.01% 3062

Other funds holding CARM

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TIAA CREF Investment Management's CARM Position: Q3 2015 in Review

TIAA CREF Investment Management sold out of Carisma Therapeutics (CARM) in Q3 2015, closing a stake of 600 shares — an estimated $34K sold.

TIAA CREF Investment Management first reported a position in CARM in Q1 2014 and held it in 6 quarters. The position peaked at $242K in Q1 2014. 30 funds tracked by Wall St. Rank hold CARM as of Q3 2015.

  • TIAA CREF Investment Management reported no remaining Carisma Therapeutics position as of Q3 2015 after selling out during the quarter.
  • TIAA CREF Investment Management sold 600 Carisma Therapeutics shares in Q3 2015, an estimated $34K.
  • TIAA CREF Investment Management first reported a position in Carisma Therapeutics in Q1 2014 and held it in 6 quarters.
  • TIAA CREF Investment Management's Carisma Therapeutics position peaked at $242K in Q1 2014.
  • 30 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2015.

Based on TIAA CREF Investment Management's 13F filing for Q3 2015, filed 13 Nov 2015.